Work

Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.1011

Authors: Angela DeMichele, James J. Harding, Melinda L. Telli, Pamela N. Munster, Rana McKay, Othon Iliopoulos, Keith W. Orford, Mark K. Bennett, James Walter Mier, Taofeek Kunle Owonikoko, Manish R. Patel, Richard D. Carvajal, Funda Meric-Bernstam, Jeffrey R. Infante

Institutions: Abramson Cancer Center, University of Pennsylvania, Memorial Sloan Kettering Cancer Center, Stanford Medicine, Stanford University, University of California, San Francisco, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, GlaxoSmithKline (United States), Calithera (United States), Beth Israel Deaconess Medical Center, Emory University, Columbia University Irving Medical Center, The University of Texas MD Anderson Cancer Center, Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, Sarah Cannon

Language: English

Topic: Cancer, Hypoxia, and Metabolism

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2730941312

Cites:

Cited by: 28

Related to: 10